Company joins exclusive club of pioneering B Corp-certified pharmaceutical companies
Opening will enable pharmaceutical company to better provide UK market with direct distribution and client-facing team. UK third direct-selling country for Provepharm, after France and the United States, expanding commercial presence in medical dye and antidote markets
Provepharm, an international, private and sustainable pharmaceutical company specialized in revitalizing molecules and Pharm-D, a healthcare and pharmaceutical company based in Malaysia with a strong foothold in Singapore, announce today their partnership to launch Proveblue® 5 mg/ml solution for injection in Malaysia.
Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection
Following GMP certification earned in 2019 for its new production unit, Provepharm now has full control over its production chain for Europe and the US.
Temporary Importation of Cefotaxime for Injection to Address Drug Shortage:
New round of funding enables pharma company to make major steps forward in its Horizon 2025 strategy.